Launch in US of long life Dynagen EL and Inogen EL defibrillators- Boston Scientific

Boston Scientific Corporation has announced the launch and first U.S. implant of its line of Extended Longevity (EL) implantable cardioverter defibrillators (ICD), including Dynagen EL and Inogen EL device models. The first EL ICD was implanted at The University of Pittsburgh Medical Center (UPMC) by Dr. Samir Saba. The device features EnduraLife battery technology that was developed with high-performance chemistry and advanced manufacturing capabilities to provide up to double the battery capacity of other ICDs. Devices with similar technology have been shown to outperform competitors' device longevities in several recent clinical studies, and the EL ICD is projected to last nearly 12 years. The EnduraLife battery technology delivers the industry's longest projected longevity, and is packaged in a device up to 11 percent smaller and 24 percent thinner than devices from other manufacturers. Increased device longevity can reduce the risk of infection and other complications over time, minimize out-of-pocket patient expenses for avoidable replacement procedures, and decrease other healthcare system costs associated with device therapy.

Comment: The battery life of 12 years is a major step ahead of competitors such as Medtronic, giving double the longevity.The longer life has an effect on patient outcomes and cost of care avoiding replacement procedures and complications.The new devices are 11% smaller and 24% thinner than Medtronics' Evera XT.